• Pliant Therapeutics will present its ongoing FORTIFY Phase 1b cancer trial at ESMO in Madrid on October 23, 2026.
• The trial is enrolling patients with advanced solid tumors resistant to immune checkpoint inhibitors to evaluate PLN-101095 combined with pembrolizumab.
• Three cohorts cover non-small cell lung cancer, high-tumor-mutational-burden tumors and clear cell renal cell carcinoma.
• The study evaluates safety, tolerability and preliminary antitumor activity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610191605PRIMZONEFULLFEED9848509) on October 19, 2026, and is solely responsible for the information contained therein.